Allergic Therapeutics announces first dosing in peanut allergy vaccine trial
- 29 March 2023
- Healthcare News
Allergy Therapeutics, a biotechnology company specialising in the treatment and diagnosis of allergic disorders, has announced the first application of VLP Peanut in peanut allergic patients has commenced.
The Phase 1 PROTECT trial is the first-in-human study evaluating the safety and tolerability of VLP Peanut in healthy and peanut allergic adult subjects and exploring preliminary proof of efficacy.
The full release can be found here.
